We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
151
Prothena Corp
PRTA
$448M
$504K 0.03%
+19,000
New +$477K
ACHN
152
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$495K 0.03%
1,491
-1,163
-44% -$3.38K
RPRX
153
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$485K 0.03%
265
-600
-69% -$11.3K
GSK icon
154
PUT
GSK
GSK
$108B
$470K 0.03%
70
-874
-93% -$56.7K
EXAS
155
DELISTED
Exact Sciences
EXAS
$464K 0.03%
+39,729
New +$456K
DNDN
156
PUT
DELISTED
DENDREON CORPORATION
DNDN
$429K 0.03%
1,436
– –
IMUC
157
PUT
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$426K 0.03%
93
+4
+4% +$379
TWTR
158
PUT
DELISTED
Twitter, Inc.
TWTR
$395K 0.03%
+62
New +$3.08K
DNDN
159
DELISTED
DENDREON CORPORATION
DNDN
$393K 0.03%
131,500
+41,700
+46% +$117K
AVNR
160
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$381K 0.02%
113,308
+46,790
+70% +$193K
CHTP
161
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$369K 0.02%
+83,200
New +$281K
FCSC
162
DELISTED
Fibrocell Science Inc.
FCSC
$363K 0.02%
5,967
-10,766
-64% -$627K
VIRX
163
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$360K 0.02%
+4
New +$4.14K
KBIO
164
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$356K 0.02%
10,081
-3,095
-23% -$104K
PLUR icon
165
PUT
Pluri
PLUR
$18.1M
$353K 0.02%
13
– –
VVUS
166
CALL
DELISTED
Vivus Inc
VVUS
$342K 0.02%
38
-40
-51% -$3.86K
ATHE
167
CALL
Alterity Therapeutics
ATHE
$82.7M
$321K 0.02%
+8
New +$2.39K
STAA icon
168
PUT
STAAR Surgical
STAA
$1.13B
$314K 0.02%
+194
New +$2.6K
CATX icon
169
Perspective Therapeutics
CATX
$327M
$311K 0.02%
62,153
-104,157
-63% -$549K
PCYC
170
DELISTED
PHARMACYCLICS INC
PCYC
$303K 0.02%
2,860
-9,490
-77% -$1.15M
PATH
171
DELISTED
NUPATHE INC COM STK
PATH
$293K 0.02%
+89,751
New +$200K
WCG
172
PUT
DELISTED
Wellcare Health Plans, Inc.
WCG
$282K 0.02%
+40
New +$2.79K
SEEL
173
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
ADXSW
174
DELISTED
Advaxis Inc Warrants
ADXSW
$276K 0.02%
+162,375
New +$219K
REGN icon
175
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
$275K 0.02%
10
-172
-95% -$49.5K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.